Valuation Abbott Laboratories Kazakhstan S.E.
Stocks
ABT_KZ
US0028241000
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Cboe BZX
15:59:55 2026-08-21 EDT
|
5-day change | 1st Jan Change | ||
| 116.65 USD | -5.93% |
|
+12.73% | -13.89% |
| 09:50am | Global markets live: Walmart, Nvidia, Ross Stores, SpaceX, Delta Air Lines… |  |
| 06:17am | TD Cowen Adjusts Price Target on Abbott Laboratories to $135 From $115, Maintains Buy Rating | MT |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 241,365 | 191,427 | 191,088 | 196,184 | 217,859 | 197,506 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -9.34% | - | - |
| Enterprise Value (EV) 1 | 249,166 | 198,318 | 198,871 | 202,693 | 222,266 | 221,445 | 218,463 | 214,773 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -0.37% | -1.35% | -1.69% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 32.7x | 25.2x | 22.5x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 4.12x | 3.95x | 3.75x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | -5.2x | 0.8x | 1.9x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.93x | 3.61x | 3.38x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 4.4x | 4x | 3.68x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 16.9x | 15x | 13.4x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 18.9x | 16.8x | 15x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 27.9x | 23.3x | 21x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 3.58% | 4.28% | 4.75% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.571 | 2.741 | 2.896 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.25% | 2.4% | 2.54% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.486 | 4.524 | 5.074 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 73.7% | 60.6% | 57.1% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,302 | 54,646 | 58,409 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 13,090 | 14,598 | 16,020 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,719 | 13,021 | 14,313 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 6,232 | 7,924 | 8,850 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 23,939 | 20,957 | 17,267 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 114.14 | 114.14 | 114.14 |
| Nbr of stocks (in thousands) | 1,714,968 | 1,743,574 | 1,736,059 | 1,734,455 | 1,738,834 | 1,730,383 | - | - |
| Announcement Date | 1/26/22 | 1/25/23 | 1/24/24 | 1/22/25 | 1/22/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.74x | 4.4x | 17.04x | 2.25% | 198B | |
| 20.92x | 3.59x | 12.63x | 3.22% | 118B | |
| 17.23x | 0.2x | 12.62x | 0.76% | 60.05B | |
| 30.79x | 7.66x | 19.56x | 1.29% | 53.18B | |
| 36.16x | 3.47x | 11.9x | 2.09% | 51.11B | |
| 36.16x | 6.36x | 19.98x | -.--% | 34.05B | |
| 42.76x | 1.23x | 11.27x | 0.18% | 28.58B | |
| 41.25x | 7.23x | 25.94x | 0.26% | 24.9B | |
| 25.39x | 3.82x | 13.43x | 1.13% | 22.98B | |
| Average | 31.49x | 4.22x | 16.04x | 1.24% | 65.61B | |
| Weighted average by Cap. | 29.67x | 4.08x | 15.61x | 1.84% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- ABT_KZ Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
